Fritextsökning
Innehållstyper
-
New ATMP center inaugurated: “In the future, we will see cell and gene therapies in all clinics”
Karolinska Institutet and Karolinska University Hospital’s new ATMP center was inaugurated in Flemingsberg, south of Stockholm. “The ATMP Center is not just a p...
-
MSD discontinues two Keytruda trials
MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.
-
NT-rådet säger nej till nya ALS-läkemedlet Qalsody
EU-kommissionen sa ja – men NT-rådet sätter stopp. Regionerna rekommenderas inte att använda det nya läkemedlet Qalsody till patienter med den neurogenerativa sjukdomen ALS.
-
Speed meets precision for high-density components
ZEISS METROTOM 800 320 kV.
-
Enkelt test kan förutsäga leversjukdom - ”Bygger på tre enkla blodprover”
Ett blodtest, utvecklat av forskare vid Karolinska institutet, kan förutsäga risken att utveckla allvarlig leversjukdom, enligt en ny studie
-
A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024
The new year brings new features for the readers of Life Science Sweden.
-
ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.
-
Enhance your expertise with your measuring software
Discover the training options in our ZEISS Metrology Portal.
-
Norway rejects national life science strategy – sees no need
The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.
-
Large study: The benefits and risks of obesity medications
Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...
-
GU Ventures AB
-
Nytt samarbete: Chat GPT flyttar in i Lundbecks laboratorier
Den danska läkemedelskoncernen Lundbeck tar hjälp av Open AI för att påskynda forskning och effektivisera arbetet inom hela verksamheten.
-
Thermo Fisher köper svenskägt bolag i mångmiljardaffär
Thermo Fisher Scientific förvärvar hälsoteknikbolaget Clario i en affär värderad till 9,4 miljarder dollar.
-
“Research is always a lot of failures and a few successes”
Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...
-
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
-
Smartzoom 100 – The New Digital Microscope for Maximum Efficiency
Free webinar July 1, 9:00-9:45 AM CEST and 5:00-5:45 PM CEST.
-
Introduction of ZEISS Imaging Systems for Super-Resolution
Webinar recording about the ZEISS Lattice SIM technology.
-
Cytel Sweden
-
Achieve Efficient, Fast Targeting of Your Sample
Step into the future of imaging technology with VersaXRM 730.
-
CT technology for when the inside matters
ZEISS METROTOM 1 now at #HandsOnMetrology.
-
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
-
Achieve Effortless, Standardized Automation with the new ZEISS Automation Interface
Simple interfaces for automated loading of CMMs.
-
Optimize Your Visibility
ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.
-
Will the FDA’s new transparency policy extend to medical devices? (Part 1)
In a significant policy shift, the FDA has begun publishing Complete Response Letters (CRLs) for drug and biologic applications that were initially rejected but...